ArticleScientific reports2025
uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The lactylation axis: bridging metabolic reprogramming and immunosuppression in the tumor microenvironment.Frontiers in immunology · 2026Review
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME), which limits treatment efficacy. Lactate, produced from pyruvate by lactate dehydrogenase A (LDHA), is known to contribute to the formation of such an immunosuppressive TME. However, it remains unclear how lactate metabolism influences immune cell populations and contributes to immunosuppression under metabolic constraints in PDAC. To address this, we investigated the mechanisms by which a high-LDHA TME promotes an immunosuppressive landscape in PDAC using single-cell RNA sequencing and multiplex immunofluorescence staining. In a mouse Ldha-knockdown (shLdha) PDAC model characterized by reduced glucose consumption and lactate production, the number of myeloid-derived suppressor cells (MDSCs) was markedly reduced compared to controls. Gene set enrichment analysis revealed lower enrichment of the cholesterol metabolism pathway in MDSCs from the shLdha group. Among cholesterol-associated genes, PLAUR, which encodes the urokinase plasminogen activator receptor (uPAR), showed the highest expression in MDSCs, particularly in monocytic MDSCs (M-MDSCs). In human PDAC samples, patients with high LDHA expression exhibited greater numbers of M-MDSCs and a higher proportion of uPAR-positive M-MDSCs compared to those with low LDHA expression. These findings provide mechanistic insights into how lactate metabolism in the high-LDHA TME modulates MDSC behavior and contributes to immunosuppression in PDAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.